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The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of
MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be
developed to achieve potent selectivity for validated MMP targets yet therapeutically spare MMP antitargets that are critical in host
protection.
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Twenty five years ago, the therapeutic strategy of controlling
cancer by broadly targeting collagenase (matrix metalloproteinase
(MMP)1), stromelysin-1 (MMP3), and gelatinase A (MMP2), the
three then known MMPs, was founded on reducing degradation of
basement membrane and extracellular matrix proteins by cancer
cells in metastasis and angiogenesis (Liotta et al, 1980; Hodgson,
1995). In the development of MMP inhibitors (MMPI) as anti-
cancer drugs, the first generation peptidomimetic compounds
(batimastat, BB94; GM-6001 ilomostat) were not orally bioavail-
able. These were superseded by second generation MMPIs from
several companies that entered phase III clinical trials to treat
many types of advanced cancer (Zucker et al, 2000; Fingleton,
2003). However, the broad spectrum MMPIs as well as those that
show partial selectivity failed in extensive phase III clinical trials
(Zucker et al, 2000; Coussens et al, 2002; Overall and Lo ´pez-Otin,
2002; Fingleton, 2003). As a family, all 23 MMPs have been
considered to be cancer drug targets, but is this correct? indeed
none were properly validated until recently (reviewed by Overall
and Kleifeld, 2006). So, can validated MMP drug targets in cancer
be therapeutically blocked by highly selective third generation
MMPIs to treat cancer?
Today, it is clear that the major role of MMPs is for homeostatic
regulation of the extracellular environment and for controlling
innate immunity (Overall, 2004; Parks et al, 2004), not simply to
degrade extracellular matrix as their name suggests. In tumori-
genesis, MMPs participate in many deregulated signaling pathways
that are used by the tumour to promote cancer cell growth and
angiogenesis, side-step apoptosis, and for evasion of protective
host responses (McCawley and Matrisian, 2001; Egeblad and Werb,
2002). These sophisticated cellular control functions represent new
avenues for the therapeutic control of cancer. Conversely, stromal
cells harness the beneficial actions of MMPs in tissue homeostasis
and innate immunity for host resistance against cancer (Overall
and Kleifeld, 2006). All MMPs exhibit some of these functions,
but MMPs -3, -8 and -9 have activities so important that when
genetically knocked out, this leads to enhanced tumorigenesis and
metastasis in some animal models of cancer (reviewed by Overall
and Kleifeld, 2006). In drug development, antitargets are those
molecules that must be therapeutically avoided to prevent
worsening of disease or because of severe adverse side effects. A
therapeutic opportunity for anticancer drugs occurs where
blocking the detrimental activities of drug targets outweighs the
loss of their beneficial actions. This opportunity was not attained
by the second generation MMPIs, which failed to show clinical
efficacy. Even worse, for patients taking the carboxylate MMPI
BAY-12-9566, small cell lung cancer metastasis worsened. Musculo-
skeletal side effects also necessitated reduced dosing in some
patients. If efficacy and adverse reactions occurred at similar
doses, this raises concerns as to whether the minimal effective
concentration was reached in all patients – no side effects might
reflect noneffective drug concentrations. Coupled with clinical trial
design and that the patient and disease stratification did not match
the preclinical animal models, MMPIs inevitably failed to control
advanced cancer (Zucker et al, 2000; Coussens et al, 2002; Overall
and Lo ´pez-Otin, 2002; Fingleton, 2003). So, for successful cancer
therapy based on MMP inhibition, the next generation of MMP
inhibitor drugs must be selective against validated MMP targets
but therapeutically spare MMP antitargets. With such selectivity,
adverse reactions might also be minimised.
MMP TARGETS AND ANTITARGETS IN CANCER
A validated drug target unambiguously contributes to the disease.
A drug that reduces the activity of a target molecule and in so
doing cures or results in improved patient outcome, is the best
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(Overall and Kleifeld, 2006). Other strong validation criteria comes
from human genetic and genomic studies; very recent studies of
MMP knockout mice crossed into transgenic oncogene-expressing
backgrounds that spontaneously develop multistage cancer, and
pathway validation using RNAi approaches ex vivo. Although the
MMP family has long been suggested as promising targets in
cancer, remarkably only three – MMP1, -2, -7 – we consider to
have been experimentally validated sufficiently to be designated as
cancer targets (reviewed in (Overall and Kleifeld, 2006)).
Reflecting the importance of MMPs in normal tissue homeo-
stasis and host resistance in cancer, we also designated three other
MMPs as validated antitargets (MMP3, -8, -9) (Overall and
Kleifeld, 2006). In view of the well-documented pro-tumorigenic
actions of MMP3 and -9 (Egeblad and Werb, 2002; Fingleton,
2003), this appears paradoxical. However, strong antitarget
activities of a MMP will override any classification of it as a drug
target, since the results of therapeutically blocking an antitarget
are potentially so detrimental or even life threatening. These
studies have been reviewed recently (Overall and Kleifeld, 2006).
The pressures of drug development by the pharmaceutical industry
coupled with the past negative clinical experiences of MMPIs
means the criteria for MMP target classification will be of the
strictest nature, as they should. Nonetheless, it is a harsh reality
that may necessitate abandoning otherwise very promising MMP
candidate drug targets. So with six MMPs categorised, the
remaining 17 MMPs await the critical confirmatory experimental
and human data for drug target classification in cancer. This is
necessary so that the active site structures of all MMPs can be
compared. Structure activity relationship (SAR) principles can
then be used in the design of next generation MMPI drugs that
discriminate between the MMP targets and antitargets in cancer.
SUBSTRATE DEGRADOMICS ELUCIDATES IN VIVO
PROTEASE FUNCTION
In target and antitarget validation, the pleiotropic roles of MMPs
in cancer need to be understood. For this, the MMP substrate
degradome (Lo ´pez-Otin and Overall, 2002) must be identified.
Since biologically relevant substrates might differ from theoretical
activities inferred from in vitro experiments – ‘just because it can,
does not mean it does’ – the best method of substrate discovery is
to identify protease-cleaved substrates in complex milieus (Lo ´pez-
Otin and Overall, 2002; Tam et al, 2004). Similarly, detecting
cleavage fragments of known substrates confirms proteolysis in
vivo and might be useful as cancer biomarkers. Recognising this,
proteomic approaches have been developed to rapidly identify new
protease substrates (Bredemeyer et al, 2004; Overall et al, 2004;
Tam et al, 2004; Butler and Overall, 2006).
Many new bioactive substrates and indirect effects on a plethora
of signaling molecules and other proteases were proteomically
identified in membrane type (MT)1-MMP-transfected MDA-MB-
231 breast carcinoma cells (Tam et al, 2004). With our recent
degradomic studies revealing similar results for other MMPs,
richly diverse bioactive substrate degradomes appear to be a
common feature of MMPs (Butler and Overall, 2006)(Dean and
Overall unpublished data). Hence, the diverse pivotal roles of
MMPs in tissue homeostasis and innate immunity are just
beginning to be recognised.
THE PROTEASE WEB
Many proteases and endogenous protease inhibitors are MMP
substrates (reviewed in Overall, 2002), and recently many more
have been identified such as secreted leukocyte protease inhibitor
and cystatins (Tam et al, 2004; Butler and Overall, 2006; Dean and
Overall unpublished data). This makes the development of MMPIs
as anticancer drugs even more challenging, since like signalling
pathways, proteolysis pathways do not function alone in vivo.
Instead, they interact to form a dynamic web – the ‘protease web’
of interconnecting proteolytic systems, cascades and circuits
(Overall and Kleifeld, 2006). Net activity of a protease, like the
web, therefore depends on the activities of many proteases and
inhibitors. In forging many cross-class and protease family
connections, MMPs are some of the key nodal proteases of the
protease web. So, by viewing proteolysis as a system, it is apparent
that protease overexpression can lead to unexpected interactions
that ripple across the protease web – much like an oscillating
spider web on trapping an insect – that is gradually restored in a
robust system. However, disruption of this balance can create an
environment that promotes tumour growth and progression. A
similar disruption of this web can occur when tissues are exposed
to MMPI drugs (Butler and Overall, 2006), resulting in indirect off-
target drug effects on unrelated proteases and their families, but all
stemming from reduced MMP activity. These must be understood
so that MMPIs can be designed to minimise perturbations in the
protease web that manifest as side effects.
TOWARD THIRD GENERATION MMPIs
In the face of selective pressures from the tissue-specific melieu at
metastasis sites or from anticancer drugs, tumour cells pheno-
typically evolve, new MMP expression profiles emerge, and the
antitarget substrates and subordinate pathways become less
effective in host defense. By inhibiting multiple MMPs, broad-
spectrum MMPIs are less likely to lead to resistance compared with
more specific drugs. Despite this, it is now clear that successful
MMPIs should ideally spare MMP antitargets by B3 log orders of
difference in Ki over targets. Chemically, this is challenging due to
similarities in MMP active sites. If this is not possible, then patient
exposure might be reduced by shorter periods of dosing or
alternative routes of administration. How then to move forward
and design highly specific inhibitor drugs of validated MMP
targets?
S1
0 specificity loop
The main sequence differences between MMP active sites reside in
specificity loop residues that form the S1
0 subsite pocket (Figure 1).
This leads to structural and chemical differences in the S1
0 subsite
that are reflected in the substrate preferences of the shallow pocket
MMPs (MMP1, 7) compared to deep pocket MMPs (2, 3, 8, 9, 12,
13). Nonetheless, most MMPIs lack specificity with only a few able
to spare the shallow S1
0 pocket MMPs by incorporating bulky or
long side chains at P1
0 (Overall and Kleifeld, 2006). Perhaps not
surprisingly, the antitarget MMPs 3, -8, -9 and also -12, a potential
antitarget (Overall and Kleifeld, 2006), have similar binding
properties in the active site (Lukacova et al, 2004). Comparative
modeling reveals that the void volumes of the MMP antitarget
S1
0pockets are very similar in size and shape (Figure 1B). This
might be reflected by similarities in specificity towards key shared
antitarget substrates involved in tumour protection. Indeed, the
peptidic substrate preferences for MMP3 and MMP8 are very
similar (Netzel-Arnett et al, 1991; Turk et al, 2001). So, MMPIs
optimised to spare either of these MMP antitargets might spare the
other.
The development of novel specific inhibitors for MMP12
(Dublanchet et al, 2005) and MMP13 (Chen et al, 2000) was
attributed to differences in the S1
0 pocket. An additional small
region termed the ‘S1
0 side-pocket’ or S1
0* was used for specifically
targeting MMP13 (Chen et al, 2000). The success of these
inhibitors clearly demonstrated the benefits of good mechanistic
and structural information for inhibitor design. The MMP active
site structure is generally rigid, but is very flexible in the S1
0 pocket
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Figure 1 Sequence alignment of every human MMP active site. (A) The amino-acid sequences of MMP catalytic domain regions containing the S1
0 subsite
forming residues (red frame) and S2 essential residues (blue frame) were aligned using T-Coffee (Notredame C, Higgins DG, Heringa J (2000) T-Coffee: a
novel method for fast and accurate multiple sequence alignment. J Mol Biol 302: 205–217) and annotated using ESPrint (Gouet P, Courcelle E, Stuart DI,
Metoz F (1999) ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 15: 305–308). The secondary structure and numbering is
based on MMP1 Protein Data bank (PDB) #1HFC. (B) Structural representation of antitarget MMPs. The catalytic domains of MMP3 (PDB:1CIZ), MMP8
(PDB: 1KBC), MMP9 (PDB:1GKD) and MMP12 (PDB: 1Y93) were structurally aligned and superimposed. The empty voids of the catalytic pockets were
calculated using CASTp (Liang J, Edelsbrunner H, Woodward C (1998) Anatomy of protein pockets and cavities: measurement of binding site geometry and
implications for ligand design. Protein Sci 7: 1884–1897) and visualised using Pymol (DeLano Scientific LLC, San Francisco, CA, USA http://www.pymol.org/)
and its CATSp plugin. The S1
0 pocket voids are in yellow, the essential S2 pocket residues at position 227 are shown in blue, and the S1
0 specificity loop is
shown in orange-red. The original structures contained a bound inhibitor in the active site, which was removed prior to calculation. Therefore, the S1
0 voids
include any structural adaptations in the molecule that were needed to accommodate the inhibitor. Although, these adaptations occurred upon bindingo f
different inhibitors, the character of the void spaces is quite similar (data not shown).
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be exploited to accommodate unfavorable binding groups in
MMPIs. Indeed, the shallow S1
0 pockets of MMP1 and MMP7 must
be able to accommodate the bulky Phe and Tyr, respectively, for
these are the P1
0 residues cleaved during in trans zymogen
autoactivation. However, active site flexibility renders SAR-based
drug design challenging since it is difficult to predict the extent of
molecular movement that can occur upon inhibitor binding. On
the other hand, ‘shape shifter’ allosteric inhibitors that exploit
active site flexibility to perturb subsite binding interactions or the
catalytic centre are promising avenues for new MMPI develop-
ment.
Zinc-binding groups
Zn
2þ-chelating hydroxamates have been favoured in MMPI design
because of superior DG values, but a number of other groups are
possible (Figure 2). However, strong Zn
2þ-chelating moieties
disproportionately drive binding and so overwhelm the contribu-
tion from the rest of the compound, reducing other opportunities
for improved specificity. Indeed, hydroxamate activity-based MMP
probes related to marimastat bound many off-target metallopro-
teinases that were not MMPs (Saghatelian et al, 2004). This may be
related to the lack of selectivity of hydroxamic acid for zinc over
other divalent transition metals, including the ability to bind metal
ions in several oxidation states such as iron (III). In addition,
the hydroxamate carbon-nitrogen bond (C[¼O]NHOH) can easily
change to the trans configuration reducing its affinity (Puerta et al,
2004).
So, is there a way to utilise binding to the catalytic Zn
2þ ion but
also develop specificity? If weaker Zn
2þ-chelation groups were
utilised, then by reducing the reliance on Zn
2þ-binding for
potency, the chemistry would have to be optimised in other parts
of the compound in order to still generate nanomolar inhibitors.
To achieve the highest binding energies, the compound would
have to be adapted for individual MMPs and so should lead to
higher specificity MMPIs. Since TIMPs do not cause the
musculoskeletal side effects that occurred with some MMPIs, then
it is possible that neither MMPs nor ADAMs are the cause of these
adverse reactions. This further supports incorporating weaker
Zn
2þ ion binding groups into the third generation MMPIs to
reduce off target binding that was seen in activity based probe
studies (Saghatelian et al, 2004). An alternative view though is that
more potent and selective zinc-binding groups might improve
MMPI specificity. For example very high affinity pyrone-based
MMPIs (Figure 2) showed nanomolar potency and selectivity for
MMP3 (Puerta et al, 2005).
Active site prime side coordination
The nonprime side of the active site has not been used in inhibitors
that reached clinical trials. By binding to both sides of the active
Zinc binding moiety Structure MMP-7 Ki
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Figure 2 The structures of zinc binding groups, their inhibitory constants, and calculated free energy for interaction with MMP catalytic zinc. The lower
free energy (DG) for interaction with MMP catalytic zinc of hydroxamate-based inhibitors is well correlated with their superior inhibitory constants relative to
other common zinc-binding groups. This attribute of hydroxamate-based inhibitors conceals the contribution of other groups in the inhibitor structure, and
therefore reduces their selectivity.
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can be exploited. In some phosphinic inhibitors (Figure 2), the
weak zinc chelating phosphinyl group was used on optimised
backbones to generate extremely potent MMPIs that were two
log orders selective for MMP11 (Cuniasse et al, 2005). These
compounds mimic the transition state in peptide cleavage with
the two phosphinic oxygens tetrahedrally orientated to the
inhibitor backbone. This also allows for the inhibitor to be
extended into the nonprime side, a feature that hydroxamate
chemistry precludes. However, the negative charge renders this
compound class membrane impermeable, limiting their distribu-
tion in vivo. Analysis of sequence alignments of the MMP active
sites confirms the active site homology and reveals a variable
residue at position 227 that defines the S2 pocket (Figure 1B). A
number of MMPs have Glu or Asp here, whereas hydrophobic
residues are found in other MMPs. By exploiting this acidic
character, inhibitor selectivity may be engendered by charge
attraction or repulsion.
Covalent inhibitors
The fear of unanticipated side effects through accumulation of
covalent-bound off targets motivates current drug development
efforts for noncovalent inhibitor classes. However, this may be
an unjustified strategy. Surprisingly, of the 317 currently licensed
drugs in the USA that inhibit an enzyme target, 35% of the 71
enzyme targets are irreversibly blocked by mechanism-based
compounds that covalently modify the target or enzyme–substrate
complex (Robertson, 2005). These drugs have proven efficacy by
targeting the catalytic mechanism rather than just focusing on
binding. Since proteolytic enzymes hydrolyze peptide or isopep-
tide bonds, this catalytic mechanism can be exploited to develop
unique drug classes. Upon binding, these suicide inhibitors or
substrates undergo a conversion of an unreactive group in the
inhibitor into a functionality reactive group that covalently
modifies residues in the active site. Since the reactive species is
formed only within the active site of the targeted enzyme, it
provides high specificity and in vivo selectivity.
A potent mechanism-based thiirane sulphur-containing anti-
MMP2 and -9 inhibitor that forms a reversible covalent bond with
the active site glutamate (Figure 2), performs impressively in an
aggressive murine model of T-cell lymphoma (Kruger et al, 2005).
Recently, the design of the prototypic inhibitor was modified and
a new generation of mechanism-based MMP2-specific MMPIs
were developed (Ikejiri et al, 2005). So, although pharmaceutical
companies would prefer to develop noncovalent inhibitors, for
short or medium duration patient dosing or in very serious
cancers, the risk of side effects may be acceptably low to consider
the use of this class of compound.
Exosite binding and allosteric inhibitors
Because the catalytic site and binding pockets of MMPs are
structurally very similar, specificity might be also achieved with
substrate-specific exosite inhibitors (Overall, 2002; Overall and
Lo ´pez-Otin, 2002). Exosites on the hemopexin C domain of MMPs
and collagen binding fibronectin type II modules in MMP2 and
-9 drive catalysis of many substrates including chemokines and
collagen (reviewed by Overall, 2002). The binding affinity of
exosite domains for substrates is typically low (10
 6–10
 7 M)o n
generally featureless sites, rendering it potentially difficult to
develop compounds that bind here. However, exosite binders may
be linked to active site inhibitors to achieve highly potent and
highly selective two-site binding inhibitors.
Moving away from ‘lock and key’ SAR principles for protease
inhibitor design might lead to new allosteric, noncompetitive
inhibitors that bind sites that are distant from the active and
substrate-binding sites. Upon binding, a conformational change
occurs in the target that reduces the catalytic rate. The individual
rates of substrate binding and active site conformational change
now become rate limiting in catalysis. Since the potency of
competitive inhibitors is reduced as the concentration of substrate
rises, allosteric noncompetitive or uncompetitive inhibitors that
bind in the presence of substrates and maintain their efficacy have
many advantages. Further, if allosteric sites are not shared by
many MMPs, this approach represents a very promising approach
for MMPI specifity.
Allosteric inhibitors might have been achieved for MMP12. A
high throughput screen aimed to find non-zinc chelating
compounds that showed additive inhibition against MMP12 over
that achieved in the presence of a hydroxamate inhibitor alone
(Dublanchet et al, 2005). Two nonpeptidic non-zinc chelating
inhibitors in the S1
0 pocket were found that could be crystallised in
the presence of an acetohydroxamate anion that bound the active
site Zn
2þ ion (Morales et al, 2004). A novel subnanomolar
nonchelating MMP13 inhibitor was also reported that binds deeply
into the S1
0 pocket of MMP13 and protrudes into the S1
0* side
pocket. In this bent conformation, it clamps around a leucyl side
chain, which is unique to MMP13 (Engel et al, 2005). However,
it is not clear whether these are true allosteric inhibitors or
functioning by competing for S1
0 subsite occupancy in deep pocket
MMPs. If such drug classes can be exploited for other MMPs, they
may form an effective new strategy to specifically inhibit MMP
drug targets.
FUTURE PERSPECTIVES
A number of crucial issues must be resolved in order for effective
treatments of cancer to be developed based on MMP inhibition.
Matrix metalloproteinase candidate targets and antitargets must be
fully validated and their biological roles in normal processes,
host protection, and cancer must be clarified. In this task, systems
biology analysis of the protease web – degradomics in its broadest
sense – is the new frontier in proteolysis research and drug
development. These approaches will be invaluable in leading
us to new perspectives in understanding disease and in identifying
new drug targets and antitargets. Exploiting a therapeutic
opportunity is an exercise in risk management. So, when does
treating a disease with a drug that unavoidably blocks some
antitarget activities outweigh the tradeoff between benefit and
harm? Even if only occurring rarely, the negative effects of
antitarget blockade will eventually manifest when large popula-
tions are exposed, risking overall drug failure and posing human
safety and litigation concerns for pharmaceutical companies.
Hence, it is critical to develop rigid drug target validation criteria
and to understand whether an antitarget is cancer type or
even disease context dependent. Do the harmful effects of
unintentionally blocking a cancer antitarget develop for all cancer
types? Do the cancer antitarget effects that lead to accelerated
carcinogenesis only occur when cancer is already present or might
cancer be initiated in some individuals if a MMP is therapeutically
inhibited in the treatment of other diseases? Hence, failure to
develop innovative chemistry that spares cancer antitargets over
MMP targets might render some MMPs as validated, but
nondruggable cancer targets. Finally, we need to understand
and avoid drug side effects through unexpected perturbations in
the protease web resulting from therapeutic inhibition of key
nodal MMPs that control the overall activity of other proteases
in the degradome. Challenging? Yes. Is there therapeutic
potential in decapitating MMP signaling cascades that promote
tumorigenesis? Yes, but this remains unexplored and is therefore
a bright light to replace the gloom following the MMPI clinical
trials.
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